Metastatic disease in the cerebellum: The LSU experience in 1981-1993

Federico L. Ampil, Anil Nanda, Brian K. Willis, Indrani Nandy, Rosemary Meehan

Research output: Contribution to journalArticlepeer-review

16 Scopus citations


We retrospectively determined the outcome of management of metastatic disease in the cerebellum (MDC) in 45 patients because MDC is considered to be more immediately life-threatening than metastases in other intracranial locations. Treatment consisted of tumor resection and radiotherapy (RR; n = 11) or of radiotherapy alone (RA; n =34). Significant differences in the median survival (15 months for RR and 3 months for RA, p = 0.005) and in survival rates at 1 year (61 ± 30% for RR and 9 ± 10% for RA, p < 0.001) and at 2 years (15 ± 22% for RR and 0% for RA, p < 0.05) were noted. This combined management program of surgery followed by radiotherapy for MDC produced a worthwhile gain in survival.

Original languageEnglish (US)
Pages (from-to)509-511
Number of pages3
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Issue number5
StatePublished - 1996
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research


  • Cerebellum
  • Metastasis
  • Radiotherapy
  • Surgery


Dive into the research topics of 'Metastatic disease in the cerebellum: The LSU experience in 1981-1993'. Together they form a unique fingerprint.

Cite this